{"content":[{"text":"death. By keeping beta cells healthy and functional, Veralox’s inhibitor may halt T1D disease \n progression and has the potential to be used at all stages of the disease.","bbox":{"left":0.118039,"top":0.091371,"width":0.740436,"height":0.03133100000000001}},{"text":"###","bbox":{"left":0.485398,"top":0.15531,"width":0.03002400000000005,"height":0.015573000000000004}},{"text":"About Veralox Therapeutics \n VERALOX Therapeutics Inc. (https://veralox.com/) is developing first-in-class therapeutics that \n target the underlying pathologies of thrombosis and type 1 diabetes. The company’s lead \n candidate, VLX-1005, will be developed initially to treat patients with heparin-induced \n thrombocytopenia (HIT) and HIT with thrombosis (HITT). Second generation therapeutic \n products are under development for type 1 diabetes (T1D) as well as other immune-mediated \n and inflammatory diseases.","bbox":{"left":0.118039,"top":0.187129,"width":0.749229,"height":0.11133000000000004}},{"text":"JDRF T1D Fund \n The JDRF T1D Fund (https://t1dfund.org/) is a venture philanthropy fund accelerating life- \n changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic \n commercial investments. Through its investments in partnership with private capital, including \n venture capital, corporations and foundations, the T1D Fund seeks to attract the private \n investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of \n those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the \n leading global organization funding T1D research, with an exclusive focus on supporting the \n best commercial opportunities. The T1D Fund will reinvest any realized gains into new \n investments to further its mission.","bbox":{"left":0.118039,"top":0.315007,"width":0.7414620000000001,"height":0.15921000000000002}},{"text":"Sanofi Ventures \n Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early- \n stage biotech and digital health companies with innovative ideas and transformative new \n products and technologies of strategic interest to Sanofi. Among these areas are rare diseases, \n vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health \n solutions. For more information, visit www.sanofiventures.com.","bbox":{"left":0.118039,"top":0.490462,"width":0.75832,"height":0.09557299999999996}},{"text":"Media Contacts:","bbox":{"left":0.118039,"top":0.60228,"width":0.138866,"height":0.015572999999999948}},{"text":"Contact@Veralox.com \n 301-360-3502","bbox":{"left":0.118039,"top":0.634401,"width":0.18020800000000003,"height":0.031331}},{"text":"JDRF T1D Fund \n Scott Lessne \n Stanton \n slessne@stantonprm.com \n 646-502-3569","bbox":{"left":0.118039,"top":0.68228,"width":0.20814,"height":0.07951199999999992}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}